
8 FAQs About Vaccination From Patients With Cardiovascular Disease
Based on the FAQ section in the ACC's 2025 Concise Clinical Guidance on vaccination in adults with CVD, this short slideshow also offers recommended answers.
The American College of Cardiology (ACC) emphasizes that vaccine hesitancy is a distinct and important barrier to preventive care in patients with
The
The ACC on August 27 issued the 2025
The ACC’s new CCG emphasizes that addressing vaccine hesitancy starts with understanding its root causes and tailoring interventions accordingly. Education from a trusted clinician, particularly in routine care, is the most effective approach. Clear explanations of vaccine benefits, expected side effects, and common misconceptions—such as the belief that influenza vaccination can cause influenza—help reduce uncertainty. In a dedicated section of the CCG, the ACC presents a number of the questions most frequently asked by adults with heart disease who are vaccine candidates, eg, about infection risk, vaccine safety, myocarditis, cost, and the need for repeated doses. All reflect concerns that fuel hesitancy.
In the short slide show above, we present the ACC's FAQs and several others based on the CCG, and the ACC's suggested departure point for an answer. Overall, the ACC sends a clear message: vaccine hesitancy is not immovable, and clinicians have a central role in guiding patients through uncertainty toward informed decisions.
Click here for a summary of How to Address Barriers to Immunization for Adults with Cardiovascular Disease .
Click here for a review of 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Adult Immunizations as Part of Cardiovascular Care.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.